Press release Archives - Inceptua Group

Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe

Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe December 28 2020, Elevar Therapeutics, Inc, a fully integrated biopharmaceutical company built…

Inceptua GroupDecember 28, 2020

Featured Press release

Inceptua Partners with Global Blood Therapeutics for an Early Access Program for Voxelotor for Patients with Sickle Cell Disease

LUXEMBOURG, Dec. 3, 2020 Inceptua announces that the company has entered into a partnership with Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company focused on discovering, developing and delivering treatments…

Inceptua GroupDecember 3, 2020

Featured Press release

Inceptua receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion

LUXEMBOURG – 25 September, 2020 – Inceptua Group – pharmaceutical company and service partner announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Jetrea®…

Inceptua GroupSeptember 25, 2020

Featured Press release

Inceptua Group Announces Partnership with BioCryst on Expanded Access Program for Patients with Hereditary Angioedema

LUXEMBOURG – June 26, 2020 –Inceptua Group – pharmaceutical company and service partner spanning throughout the product lifecycle – from clinical trial comparator sourcing, packaging, labelling, and distribution solutions, through…

Inceptua GroupJune 26, 2020

Featured Press release

Global License Agreement a Building Block in Strategic Growth Plans

LUXEMBOURG – 23 March, 2020 – Inceptua – pharmaceutical company and service partner - and biopharmaceutical company Oxurion have announced a global license agreement for the commercialization of JETREA®, a…

Inceptua GroupMarch 23, 2020

Featured Press release

Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

Press release: Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA® Oxurion announces the signing of a JETREA® global license agreement with Inceptua Group. JETREA® is…

Inceptua GroupMarch 13, 2020

Featured Press release

Inceptua and Portola enter exclusive distribution agreement for Ondexxya®

LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – Inceptua, a global pharmaceutical company and service partner and Portola - US developer and manufacturer of therapeutic agents focusing on thrombosis…

Inceptua GroupFebruary 7, 2020

Featured Press release

Inceptua appoints new Head of Asia-Pacific, Clinical Trial Services

Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling…

Inceptua GroupFebruary 5, 2020

Press release

Inceptua and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

NEWTOWN, PA., and LUXEMBOURG, Dec 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with…

Inceptua GroupDecember 6, 2019

Press release

Inceptua appoints new President North America

To further strengthen its position as a leading pharmaceutical company and service partner, Inceptua appoints Paul Wituschek as President North America effective 1 January, 2020. Paul will take on the…

Inceptua GroupDecember 5, 2019

1 2 Next